2.68

0.37% -0.010

After Hours: 2.72 0.04 +1.49%

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.68, with a volume of 7.98M. It is down -0.37% in the last 24 hours and up +3.88% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$2.69

Open:

$2.63

24h Volume:

7.98M

Relative Volume:

3.80

Market Cap:

$902.00M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-6.5366

EPS:

-0.41

Net Cash Flow:

$-68.07M

1W Performance:

+2.68%

1M Performance:

+3.88%

6M Performance:

-11.55%

1Y Performance:

+90.07%

1-Day Range:

$2.57

$2.76

1-Week Range:

$2.51

$2.865

52-Week Range:

$1.43

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

203

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	2.68	902.00M	0	-75.80M	-68.07M	-0.35
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

Dec 20, 2024

Wellington Management Group LLP Purchases 283,642 Shares of Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 20, 2024

Dec 19, 2024

Nuvation Bio (NYSE:NUVB) Trading Up 5%Still a Buy? - MarketBeat

Dec 19, 2024

Dec 18, 2024

Verition Fund Management LLC Sells 13,409 Shares of Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Dec 18, 2024

Dec 15, 2024

Charles Schwab Investment Management Inc. Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - Defense World

Dec 15, 2024

Dec 13, 2024

Nuvation Bio's SWOT analysis: taletrectinib drives stock outlook amid pipeline shifts - Investing.com

Dec 13, 2024

Clear Street sets Nuvation Bio at Buy with $5 target By Investing.com - Investing.com South Africa

Dec 13, 2024

Clear Street sets Nuvation Bio at Buy with $5 target - Investing.com

Dec 13, 2024

Dec 12, 2024

Point72 Asset Management L.P. Takes Position in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 12, 2024

Dec 10, 2024

Nuvation Bio Inc (NYSE: NUVB) Drops -1.75 Percent In Recent Session, Why Are You Interested? - Stocks Register

Dec 10, 2024

Frazier Life Sciences Management L.P. Acquires New Position in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 10, 2024

Dec 08, 2024

Nuvation Bio (NYSE:NUVB) Shares Gap Down – What’s Next? - Defense World

Dec 08, 2024

Dec 07, 2024

Wexford Capital LP Has $1.49 Million Stock Position in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 07, 2024

Fmr LLC Has $66.96 Million Stake in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat

Dec 07, 2024

Nuvation Bio (NYSE:NUVB) Shares Gap DownHere's What Happened - MarketBeat

Dec 07, 2024

Nov 26, 2024

Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire

Nov 26, 2024

Nov 20, 2024

Nuvation Bio's SWOT analysis: taletrectinib drives stock potential amid challenges - Investing.com India

Nov 13, 2024

FMR LLC Bolsters Stake in Nuvation Bio Inc - GuruFocus.com

Nov 13, 2024

Nov 12, 2024

Nuvation Bio to Present at the Jefferies London Healthcare Conference - Business Wire

Nov 12, 2024

Nov 11, 2024

What is Wedbush's Estimate for Nuvation Bio FY2024 Earnings? - MarketBeat

Nov 11, 2024

Nov 08, 2024

Nuvation Bio (NYSE:NUVB) Shares Gap Up After Analyst Upgrade - MarketBeat

Nov 08, 2024

Nuvation Bio’s Global Challenges: Navigating Risks in China Amid Geopolitical Tensions - TipRanks

Nov 08, 2024

Nov 07, 2024

Royal Bank of Canada Increases Nuvation Bio (NYSE:NUVB) Price Target to $6.00 - MarketBeat

Nov 07, 2024

Nuvation Bio reports Q3 EPS (15c, consensus (13c) - TipRanks

Nov 07, 2024

Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace

Nov 07, 2024

Nov 06, 2024